Germline and Somatic Mutations in Prostate Cancer: Focus on Defective DNA Repair, PARP Inhibitors and Immunotherapy
Alessia Cimadamore, Antonio López-Beltrán, Francesco Massari, Matteo Santoni, Roberta Mazzucchelli, Marina Scarpelli, Andrea Benedetto Galosi, Liang Cheng, Rodolfo Montironi
Abstract
The understanding that PCa harbors mutations in the DNA repair genes has emerged together with the development of PARP inhibitors, that is, drugs that are designed to target DNA repair deficient and BRCA-mutated cancer "
Topics & Concepts
Pathological anatomyMedicineProstate cancerPathologicalOncologyInternal medicineCancerFamily medicinePathologyProstate Cancer Treatment and ResearchPARP inhibition in cancer therapyProstate Cancer Diagnosis and Treatment